Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

1998 • 2,668 citations

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 • 821 citations

Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources.

1977 • 660 citations

Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

1999 • 596 citations

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

2001 • 421 citations

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

2001 • 278 citations

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

2002 • 240 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 202 citations

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

2001 • 195 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 180 citations

Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

2001 • 169 citations

Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia

1993 • 159 citations

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

2002 • 138 citations

Myelodysplastic syndrome is not merely “preleukemia”

2002 • 131 citations

Differences in CD33 Intensity Between Various Myeloid Neoplasms

2002 • 123 citations

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

2000 • 104 citations

EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein

2001 • 80 citations

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

2003 • 73 citations

Veno-occlusive disease of the liver

2000 • 66 citations

Angiogenesis in Acute Myeloid Leukemia and Myelodysplastic Syndrome

2001 • 63 citations

CD33 as a Target for Selective Ablation of Acute Myeloid Leukemia

2002 • 45 citations

Management of Hepatic Sinusoidal Obstruction Syndrome Following Treatment with Gemtuzumab Ozogamicin (Mylotarg®)

2002 • 41 citations

Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.

1987 • 39 citations

Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia

2001 • 39 citations

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

2003 • 32 citations

Deleted Work

1955 • 0 citations